Bio-Rad Laboratories (BIO) Q3 Earnings Miss Estimates

Core Viewpoint - Bio-Rad Laboratories reported quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share, but showing an increase from $2.01 per share a year ago [1][2]. Financial Performance - The company posted revenues of $653 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.24% and showing a slight increase from $649.73 million year-over-year [3]. - The earnings surprise for the quarter was -1.74%, while the previous quarter saw a positive surprise of +35.23% with actual earnings of $2.61 compared to an expected $1.93 [2]. Market Performance - Bio-Rad shares have increased by approximately 0.6% since the beginning of the year, in contrast to the S&P 500's gain of 17.2% [4]. - The current Zacks Rank for Bio-Rad is 4 (Sell), indicating expectations of underperformance in the near future [7]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $2.57 on revenues of $693.11 million, and for the current fiscal year, it is $10.02 on revenues of $2.58 billion [8]. - The Medical - Products industry, to which Bio-Rad belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [9].